GSK to Acquire Aiolos Bio for ~$1.4B
Shots:
- GSK has entered into an agreement to acquire Aiolos Bio to expand its respiratory pipeline by receiving access to Aiolos’ lead molecules incl. AIO-001
- AIO-001 is a long-acting anti-thymic stromal lymphopoietin (TSLP) mAb that is expected to be evaluated in a P-II clinical trial for the treatment of patients with asthma. Moreover, Aiolos received the exclusive license for AIO-001 outside of Greater China by Jiangsu Hengrui Pharmaceuticals
- As per the agreement, Aiolos will receive an up front payment of $1B along with $400M in success-based regulatory milestone payments. Additionaly, GSK will owe Jiangsu Hengrui Pharmaceuticals certain success-based milestone payments plus tiered royalties
Ref: GSK | Image: GSK
Related News:- GSK Signs a License Agreement with Hansoh Pharma for HS-20093 to Treat Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
